Abstract
A new monocyclic beta-lactam antibiotic, SQ26,776, was evaluated in vitro against clinical isolates, and its activity was compared with that of other cephalosporins, penicillins, and aminoglycosides. This compound was very active against the majority of the aerobic gram-negative bacilli tested, including 47 multiresistant strains. It had no activity against the gram-positive cocci. It also showed activity comparable to that of moxalactam, ceftazidime, ceftriaxone, thienamycin, and tobramycin. It was superior to mezlocillin. The in vitro activity suggests that SQ26,776 should prove useful in settings in which the most likely pathogens are gram-negative bacilli.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Fass R. J. In vitro activity of LY127935. Antimicrob Agents Chemother. 1979 Oct;16(4):503–509. doi: 10.1128/aac.16.4.503. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hinkle A. M., Bodey G. P. In vitro evaluation of Ro 13-9904. Antimicrob Agents Chemother. 1980 Oct;18(4):574–578. doi: 10.1128/aac.18.4.574. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hinkle A. M., LeBlanc B. M., Bodey G. P. In vitro evaluation of cefoperazone. Antimicrob Agents Chemother. 1980 Mar;17(3):423–427. doi: 10.1128/aac.17.3.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Imada A., Kitano K., Kintaka K., Muroi M., Asai M. Sulfazecin and isosulfazecin, novel beta-lactam antibiotics of bacterial origin. Nature. 1981 Feb 12;289(5798):590–591. doi: 10.1038/289590a0. [DOI] [PubMed] [Google Scholar]
- Le Moal M., Koob G. F., Koda L. Y., Bloom F. E., Manning M., Sawyer W. H., Rivier J. Vasopressor receptor antagonist prevents behavioural effects of vasopressin. Nature. 1981 Jun 11;291(5815):491–493. doi: 10.1038/291491a0. [DOI] [PubMed] [Google Scholar]
- Olexy V. M., Bird T. J., Grieble H. G., Farrand S. K. Hospital isolates of Serratia marcescens transferring ampicillin, carbenicillin, and gentamicin resistance to other gram-negative bacteria including Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1979 Jan;15(1):93–100. doi: 10.1128/aac.15.1.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schimpff S. C., Greene W. H., Young V. M., Wiernik P. H. Pseudomonas septicemia: incidence, epidemiology, prevention and therapy in patients with advanced cancer. Eur J Cancer. 1973 Jun;9(6):449–455. doi: 10.1016/0014-2964(73)90110-2. [DOI] [PubMed] [Google Scholar]